Allogeneic platelet transfusions prevent murine T-cell-mediated immune thrombocytopenia

Blood

Volumn 123, Issue 3, 2014, Pages 422-427

  Li, Guo ^a,b,c   Yang, Lei ^a,b   Speck, Edwin R ^a,b,d   Aslam, Rukhsana ^a,b,d   Kim, Michael ^a,b   McKenzie, Christopher G J ^a,b,d   Lazarus, Alan H ^a,b,c,d   Ni, Heyu ^a,b,c   Hou, Ming ^e   Freedman, John ^a,c   Semple, John W ^a,b,c,d  

^a Toronto Platelet Immunobiology Group   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d CANADIAN BLOOD SERVICES   (Canada)

^e SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; IMMUNOGLOBULIN G ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; THROMBOCYTE ANTIBODY; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN G;

ALLOGENEIC PLATELET TRANSFUSION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BONE MARROW; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNE RESPONSE; IMMUNE THROMBOCYTOPENIA; KNOCKOUT MOUSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MEGAKARYOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; ANIMAL; BAGG ALBINO MOUSE; BONE MARROW CELL; C57BL MOUSE; CYTOLOGY; DISEASE MODEL; GENETICS; IMMUNOLOGY; METABOLISM; METHODOLOGY; SCID MOUSE; SPLEEN; TIME;

ANIMALS; BONE MARROW CELLS; DISEASE MODELS, ANIMAL; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNOGLOBULIN G; INTEGRIN BETA3; MEGAKARYOCYTES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, SCID; PLATELET TRANSFUSION; SPLEEN; T-LYMPHOCYTES; THROMBOCYTOPENIA; TIME FACTORS;

EID: 84897019921     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-08-523308     Document Type: Article

References (37)

1. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11): 2386-2393.
2. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-186.
3. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26):6511-6521.
4. Harrington WJ, Minnich V, Hollingsworth JW, Moore CV. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med. 1951;38(1):1-10.
5. Shulman NR, Weinrach RS, Libre EP, Andrews HL. The role of the reticuloendothelial system in the pathogenesis of idiopathic thrombocytopenic purpura. Trans Assoc Am Physicians. 1965;78: 374-390.
6. Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003; 102(3):887-895. (Pubitemid 36917780)
7. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103(4):1364-1369. (Pubitemid 38168649)
8. Brighton TA, Evans S, Castaldi PA, Chesterman CN, Chong BH. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood. 1996;88(1):194-201. (Pubitemid 26230687)
9. Kiefel V, Freitag E, Kroll H, Santoso S, Mueller- Eckhardt C. Platelet autoantibodies (IgG, IgM, IgA) against glycoproteins IIb/IIIa and Ib/IX in patients with thrombocytopenia. Ann Hematol. 1996;72(4):280-285. (Pubitemid 26125827)
10. McMillan R. Antiplatelet antibodies in chronic adult immune thrombocytopenic purpura: assays and epitopes. J Pediatr Hematol Oncol. 2003; 25(Suppl 1):S57-S61. (Pubitemid 37517921)
11. McMillan R, Wang L, Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost. 2003;1(3):485-491.
12. Fabris F, Scandellari R, Ruzzon E, Randi ML, Luzzatto G, Girolami A. Platelet-associated autoantibodies as detected by a solid-phase modified antigen capture ELISA test (MACE) are a useful prognostic factor in idiopathic thrombocytopenic purpura. Blood. 2004;103(12): 4562-4564. (Pubitemid 38745983)
13. Najaoui A, Bakchoul T, Stoy J, et al. Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP). Eur J Haematol. 2012;88(2):167-174.
14. Olsson B, Andersson PO, Jernas M, et al. T-cellmediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9(9):1123-1124. (Pubitemid 37173694)
15. Zhang F, Chu X, Wang L, et al. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol. 2006; 76(5):427-431.
16. Zhao C, Li X, Zhang F, Wang L, Peng J, Hou M. Increased cytotoxic T-lymphocyte-mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies. Haematologica. 2008;93(9): 1428-1430.
17. Chow L, Aslam R, Speck ER, et al. A murine model of severe immune thrombocytopenia is induced by antibody- and CD81 T cell-mediated responses that are differentially sensitive to therapy. Blood. 2010;115(6):1247-1253.
18. Slichter SJ. Controversies in platelet transfusion therapy. Annu Rev Med. 1980;31:509-540.
19. Hirsch EO, Gardner FH. The transfusion of human blood platelets with a note on the transfusion of granulocytes. J Lab Clin Med. 1952; 39(4):556-569.
20. Han T, Stutzman L, Cohen E, Kim U. Effect of platelet transfusion on hemorrhage in patients with acute leukemia. An autopsy study. Cancer. 1966;19(12):1937-1942.
21. Thachil J. The myths about platelet transfusions in immune-mediated thrombocytopenias. Br J Haematol. 2010;150(4):494-495.
22. Carr JM, Kruskall MS, Kaye JA, Robinson SH. Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med. 1986;80(6): 1051-1054.
23. Salama A, Kiesewetter H, Kalus U, Movassaghi K, Meyer O. Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia. Thromb Haemost. 2008; 100(5):762-765.
24. Spahr JE, Rodgers GM. Treatment of immunemediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients. Am J Hematol. 2008;83(2):122-125.
25. Kaech SM, Ahmed R. Memory CD81 T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat Immunol. 2001;2(5):415-422. (Pubitemid 33706139)
26. Bousso P, Robey E. Dynamics of CD81 T cell priming by dendritic cells in intact lymph nodes. Nat Immunol. 2003;4(6):579-585. (Pubitemid 36701342)
27. Blumberg N, Masel D, Mayer T, Horan P, Heal J. Removal of HLA-A,B antigens from platelets. Blood. 1984;63(2):448-450. (Pubitemid 14188896)
28. Kao KJ, Cook DJ, Scornik JC. Quantitative analysis of platelet surface HLA by W6/32 anti- HLA monoclonal antibody. Blood. 1986;68(3): 627-632. (Pubitemid 16008161)
29. Kao KJ. Plasma and platelet HLA in normal individuals: quantitation by competitive enzymelinked immunoassay. Blood. 1987;70(1):282-286. (Pubitemid 17111275)
30. Kao KJ. Selective elution of HLA antigens and beta 2-microglobulin from human platelets by chloroquine diphosphate. Transfusion. 1988; 28(1):14-17.
31. Neum? uller J, Tohidast-Akrad M, Fischer M, Mayr WR. Influence of chloroquine or acid treatment of human platelets on the antigenicity of HLA and the 'thrombocyte-specific' glycoproteins Ia/IIa, IIb, and IIb/IIIa. Vox Sang. 1993;65(3):223-231. (Pubitemid 23291061)
32. Ghio M, Contini P, Mazzei C, et al. Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood. 1999;93(5):1770-1777. (Pubitemid 29102506)
33. Gouttefangeas C, Diehl M, Keilholz W, Hörnlein RF, Stevanović S, Rammensee HG. Thrombocyte HLA molecules retain nonrenewable endogenous peptides of megakaryocyte lineage and do not stimulate direct allocytotoxicity in vitro. Blood. 2000;95(10):3168-3175. (Pubitemid 30321169)
34. Aslam R, Speck ER, Kim M, Freedman J, Semple JW. Transfusion-related immunomodulation by platelets is dependent on their expression of MHC Class I molecules and is independent of white cells. Transfusion. 2008;48(9):1778-1786.
35. Houwerzijl EJ, Blom NR, van der Want JJ, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood. 2004;103(2): 500-506. (Pubitemid 38140080)
36. Li S, Wang L, Zhao C, Li L, Peng J, Hou M. CD81 T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura. Br J Haematol. 2007;139(4):605-611. (Pubitemid 350043806)
37. Yang L, Wang L, Zhao CH, et al. Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia. Blood. 2010; 116(20):4307-4316.